Oncotarget

Corrections:

Correction: Nerofe+ldDox releases c-Jun from nuclear ST2 to reprogram the immune microenvironment in mtKRAS tumors

PDF  |  How to cite

Oncotarget. 2026; 17:209-209. https://doi.org/10.18632/oncotarget.28859

Joel Ohana1, Uziel Sandler1,2, Benjamin A. Weinberg3, Stephen Liu3, Yoram Devary1,

1Immune System Key (ISK) Ltd., Jerusalem 9746009, Israel
2Department of Bio-Informatics, Lev Academic Center (JCT), Jerusalem 91160, Israel
3Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA

Published: April 24, 2026

This article has been corrected:This article has been corrected: The authors of the article have provided a correction for the “Conflicts of Interest” section. The corrected text is shown below.

CONFLICTS OF INTEREST

Joel Ohana, Uziel Sandler, and Yoram Devary are affiliated with Immune System Key (ISK) Ltd., which is involved in the development of Nerofe, the compound investigated in this study. This affiliation represents a potential competing interest.

Original article: Oncotarget. 2025; 16:848-857. DOI: https://doi.org/10.18632/oncotarget.28820.